Royce & Associates LP Has $3.08 Million Stock Position in Dynavax Technologies Corporation (NASDAQ:DVAX)

Key Points

• Royce & Associates LP reduced its stake in Dynavax Technologies Corporation by 34.5%, owning 237,599 shares worth approximately $3.08 million after selling 125,220 shares in the first quarter.
• Dynavax Technologies reported a loss of $0.11 EPS for the last quarter, missing analysts' expectations, and had revenue of $68.16 million, below the consensus estimate.
• Analysts have lowered ratings for Dynavax Technologies, with the Goldman Sachs Group setting a sell rating and a target price drop from $12.00 to $10.00.

Royce & Associates LP lowered its position in Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) by 34.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 237,599 shares of the biopharmaceutical company's stock after selling 125,220 shares during the quarter. Royce & Associates LP owned 0.19% of Dynavax Technologies worth $3,082,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale acquired a new position in Dynavax Technologies during the 1st quarter worth $30,000. Russell Investments Group Ltd. raised its stake in shares of Dynavax Technologies by 96.5% in the 4th quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 1,169 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Dynavax Technologies in the 4th quarter valued at about $35,000. GAMMA Investing LLC raised its stake in shares of Dynavax Technologies by 88.4% in the 1st quarter. GAMMA Investing LLC now owns 7,729 shares of the biopharmaceutical company's stock valued at $100,000 after purchasing an additional 3,627 shares in the last quarter. Finally, Moloney Securities Asset Management LLC acquired a new stake in shares of Dynavax Technologies in the 1st quarter valued at about $131,000. Institutional investors and hedge funds own 96.96% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on DVAX shares. The Goldman Sachs Group cut their price objective on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a research note on Thursday, April 17th. Wall Street Zen lowered Dynavax Technologies from a "buy" rating to a "hold" rating in a research report on Tuesday, May 6th. Finally, JMP Securities dropped their price target on Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating on the stock in a research report on Wednesday, May 7th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $24.00.

Dynavax Technologies Trading Down 0.8%

NASDAQ DVAX traded down $0.09 on Thursday, hitting $11.09. 256,286 shares of the stock were exchanged, compared to its average volume of 2,115,382. Dynavax Technologies Corporation has a 52-week low of $9.22 and a 52-week high of $14.63. The company has a debt-to-equity ratio of 0.49, a current ratio of 11.93 and a quick ratio of 10.84. The company has a market capitalization of $1.33 billion, a price-to-earnings ratio of -21.30 and a beta of 1.03. The company's 50-day moving average price is $10.33 and its two-hundred day moving average price is $11.63.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last released its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.14). Dynavax Technologies had a negative net margin of 20.39% and a positive return on equity of 3.59%. The business had revenue of $68.16 million for the quarter, compared to analysts' expectations of $70.01 million. Research analysts predict that Dynavax Technologies Corporation will post 0.32 EPS for the current year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.